Not in Chicago: It’s that time of the year when my inbox rapidly fills up with folks wanting to know which were selections our winners and losers from the annual ASCO meeting.
Happy or surreal days?
There are several different ways we can organise this analysis such as Top 10 selections, by company, by trials, by product, by tumour type, by disease setting etc. The first is undoubtedly easier and shorter to write, but in general it’s really hard to pick five winners and five losers to debate and some years are more mixed in any case.
At BSB we almost rarely think about oncology R&D in terms of companies, stocks, or even individual studies per se, so this leaves organising products by tumour type and subsets.
In part 1 today we are going to focus on hematology and key developments in this area. What was under-rated, over-rated and what bombed?
There are several developments which made our short list and here we cover the highs and lows as well as a pithy ratings scale at the end. Be warned, there are likely a few surprises in store…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the ASCO meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
Friday at #ASH19 – remains of the day or hope springs eternal with sunrise on Saturday morning?
Orlando: The annual meeting of the American Society of Hematology or ASH (Twitter #ASH19) is one of the four key Majors on cancer-related related research meeting circuit that BSB attends each year.
Just as golf has the Masters, the US Open, the Open, and PGA championships, so those on the cancer new product development circuit attend AACR, ASCO, ESMO, and ASH.
This year ASH is in sunny Orlando where you have to compete with the tourists for Uber rides if you want to venture to restaurants or events in the area.
Friday at ASH has traditionally been associated with the satellite symposia, colloquially known as “Super Fridays” that CME companies or organizations such as the Leukemia Lymphoma Society have traditionally run, but in recent years ASH has put on its own Friday events to compete with both the industry satellites and also academic events such as the BMT Winter Workshop we have attended in the past. More choice is good on one hand, but bad on the other in that something has to give way.
Ron Levy (Stanford) and Stephen Ansell (Mayo) blazed the trail a few years ago with their Friday Scientific Workshop on Tumor Immune Interactions in Lymphoid malignancies. Regular BSB readers may recall the interview at ASH16 with Dr Levy where he reviewed some of the data in that year’s workshop (See post: Targeting the tumour environment in lymphomas.)
This year on Friday at ASH19 there were multiple scientific workshops you could attend. What were some of the presentations that caught our personal attention, what can we learn from them and why did they matter?
To learn more from our latest oncology conference insights and get a heads up on our latest ASH Coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.